Product Code: GVR-4-68041-029-5
U.S. Gastrointestinal Surgery Procedures Market Summary
The U.S. gastrointestinal surgery procedures market size was valued at USD 18.9 billion in 2025 and is projected to grow from USD 19.5 billion in 2026 to USD 24.4 billion by 2033, at a CAGR of 3.2% from 2026 to 2033. The market is supported by the large and continuing burden of digestive diseases, which creates a substantial need for surgical diagnosis and treatment.
Gastrointestinal conditions such as colorectal cancer, inflammatory bowel disease, diverticular disease, gallbladder disorders, and obesity-related digestive complications contribute to the demand for procedures across hospitals and ambulatory surgical centers. Colorectal cancer remains an important contributor to gastrointestinal surgical demand; according to the latest CDC data, 155,662 new colorectal cancer cases were reported in the U.S. in 2023, while 54,468 people died from colorectal cancer in 2024. The continued disease burden supports demand for procedures such as colectomy, bowel resection, rectal surgery, cholecystectomy, and other abdominal surgeries. The increasing prevalence of obesity is another important driver, particularly for bariatric and metabolic gastrointestinal procedures.
CDC data show that 40.3% of U.S. adults had obesity during August 2021-August 2023, while 2024 surveillance found that every U.S. state and territory had an adult obesity prevalence of at least 25%. The high obesity burden increases the patient population eligible for surgical weight-management procedures and is also associated with several conditions that can require gastrointestinal or abdominal surgery. As a result, the continued prevalence of obesity is expected to support demand for procedures such as sleeve gastrectomy and gastric bypass, while also increasing the need for surgical management of related gastrointestinal and hepatobiliary conditions.
The shift toward minimally invasive and robotic-assisted surgery is further strengthening market growth. Laparoscopic and robotic approaches are increasingly used for colorectal, bariatric, gallbladder, and other abdominal procedures because they can provide smaller incisions, improved visualization, greater instrument control, and potentially faster recovery compared with conventional open surgery. This trend is being reinforced by continued investment in robotic surgical platforms. For example, the FDA granted De Novo authorization for Johnson & Johnson MedTech's OTTAVA Robotic Surgical System on July 21, 2026, adding another robotic platform to the U.S. surgical market. The increasing availability of advanced robotic and laparoscopic technologies is therefore expanding technology options for hospitals and surgeons and supporting the transition toward minimally invasive gastrointestinal procedures.
Government-supported colorectal cancer screening is also indirectly supporting the gastrointestinal surgery ecosystem by encouraging earlier detection and treatment of colorectal disease. CMS continues to cover colorectal cancer screening as a Medicare preventive service, including screening colonoscopy and other approved screening tests. Earlier identification of colorectal abnormalities can lead to additional diagnostic evaluation and, when cancer or advanced disease is identified, surgical treatment. This creates a pathway from screening and diagnosis to surgical management, supporting continued demand for colorectal procedures in the U.S.
U.S. Gastrointestinal Surgery Procedures Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. gastrointestinal surgery procedures market report based on CPT, indication, procedure urgency, and end use:
- CPT Outlook (Revenue, USD Billion, 2021 - 2033)
- 43020-43135, 43279-43499
- 44005-44346, 44500-44799, 44800-44899, 44900-44979, 45000-45190, 45395-45999, 46020-46505, 46700-46999
- 47010-47399, 47400-47480, 47562-47999, 48020, 48105-48160, 48500-48999
- 43644-43645; 43770-43775; 43845-43848; 43886-43888
- Indication Outlook (Revenue, USD Billion, 2021 - 2033)
- Cancer
- Benign GI Disorders
- Acute/Emergency Conditions
- Obesity
- Other Conditions
- Procedure Urgency Outlook (Revenue, USD Billion, 2021 - 2033)
- Elective
- Urgent
- Emergency
- End Use Outlook (Revenue, USD Billion, 2021 - 2033)
- Hospitals
- Ambulatory Surgical Centers
- Specialty Surgical Centers
- Other
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Segment Definitions
- 1.2.1. CPT
- 1.2.2. Indication
- 1.2.3. Procedure Urgency
- 1.2.4. End Use
- 1.2.5. Country scope
- 1.2.6. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.4.5.1. Data for primary interviews in North America
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. CPT Outlook
- 2.2.2. Indication Outlook
- 2.2.3. Procedure Urgency Outlook
- 2.2.4. End Use Outlook
- 2.3. Competitive Insights
Chapter 3. U.S. Gastrointestinal Surgery Procedures Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. U.S. Gastrointestinal Surgery Procedures Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Bargaining power of suppliers
- 3.3.1.2. Bargaining power of buyers
- 3.3.1.3. Threat of substitutes
- 3.3.1.4. Threat of new entrants
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Economic landscape
- 3.3.2.3. Social landscape
- 3.3.2.4. Technological landscape
- 3.3.2.5. Environmental landscape
- 3.3.2.6. Legal landscape
Chapter 4. U.S. Gastrointestinal Surgery Procedures Market: CPT Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. U.S. Gastrointestinal Surgery Procedures Market: CPT Movement Analysis
- 4.3. U.S. Gastrointestinal Surgery Procedures Market by CPT Outlook (USD Billion)
- 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
- 4.5. 43020-43135, 43279-43499
- 4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 4.6. 44005-44346, 44500-44799, 44800-44899, 44900-44979, 45000-45190, 45395-45999, 46020-46505, 46700-46999
- 4.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 4.7. 47010-47399, 47400-47480, 47562-47999, 48020, 48105-48160, 48500-48999
- 4.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 4.8. 43644-43645; 43770-43775; 43845-43848; 43886-43888
- 4.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 5. U.S. Gastrointestinal Surgery Procedures Market: Indication Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. U.S. Gastrointestinal Surgery Procedures Market: Indication Movement Analysis
- 5.3. U.S. Gastrointestinal Surgery Procedures Market by Indication Outlook (USD Billion)
- 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
- 5.5. Cancer
- 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 5.6. Benign GI Disorders
- 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 5.7. Acute/Emergency Conditions
- 5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 5.8. Obesity
- 5.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 5.9. Other Conditions
- 5.9.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 6. U.S. Gastrointestinal Surgery Procedures Market: Procedure Urgency Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. U.S. Gastrointestinal Surgery Procedures Market: Procedure Urgency Movement Analysis
- 6.3. U.S. Gastrointestinal Surgery Procedures Market by Procedure Urgency Outlook (USD Billion)
- 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
- 6.5. Elective
- 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 6.6. Urgent
- 6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 6.7. Emergency
- 6.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 7. U.S. Gastrointestinal Surgery Procedures Market: End Use Estimates & Trend Analysis
- 7.1. Segment Dashboard
- 7.2. U.S. Gastrointestinal Surgery Procedures Market: End Use Movement Analysis
- 7.3. U.S. Gastrointestinal Surgery Procedures Market by End Use Outlook (USD Billion)
- 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
- 7.5. Hospitals
- 7.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.6. Ambulatory Surgical Centers
- 7.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.7. Specialty Surgical Centers
- 7.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.8. Other
- 7.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 8. Competitive Landscape
- 8.1. Market Participant Categorization
- 8.2. Key Company Profiles
- 8.2.1. Johnson & Johnson MedTech / Ethicon
- 8.2.1.1. Company Overview
- 8.2.1.2. Financial Performance
- 8.2.1.3. Product/Service Benchmarking
- 8.2.1.4. Strategic Initiatives
- 8.2.2. Medtronic
- 8.2.2.1. Company Overview
- 8.2.2.2. Financial Performance
- 8.2.2.3. Product/Service Benchmarking
- 8.2.2.4. Strategic Initiatives
- 8.2.3. Stryker
- 8.2.3.1. Company Overview
- 8.2.3.2. Financial Performance
- 8.2.3.3. Product/Service Benchmarking
- 8.2.3.4. Strategic Initiatives
- 8.2.4. Intuitive Surgical
- 8.2.4.1. Company Overview
- 8.2.4.2. Financial Performance
- 8.2.4.3. Product/Service Benchmarking
- 8.2.4.4. Strategic Initiatives
- 8.2.5. CONMED
- 8.2.5.1. Company Overview
- 8.2.5.2. Financial Performance
- 8.2.5.3. Product/Service Benchmarking
- 8.2.5.4. Strategic Initiatives
- 8.2.6. Applied Medical
- 8.2.6.1. Company Overview
- 8.2.6.2. Financial Performance
- 8.2.6.3. Product/Service Benchmarking
- 8.2.6.4. Strategic Initiatives
- 8.2.7. B. Braun
- 8.2.7.1. Company Overview
- 8.2.7.2. Financial Performance
- 8.2.7.3. Product/Service Benchmarking
- 8.2.7.4. Strategic Initiatives
- 8.2.8. Teleflex
- 8.2.8.1. Company Overview
- 8.2.8.2. Financial Performance
- 8.2.8.3. Product/Service Benchmarking
- 8.2.8.4. Strategic Initiatives
- 8.2.9. Olympus
- 8.2.9.1. Company Overview
- 8.2.9.2. Financial Performance
- 8.2.9.3. Product/Service Benchmarking
- 8.2.9.4. Strategic Initiatives
- 8.2.10. KARL STORZ
- 8.2.10.1. Company Overview
- 8.2.10.2. Financial Performance
- 8.2.10.3. Product/Service Benchmarking
- 8.2.10.4. Strategic Initiatives
- 8.2.11. BD
- 8.2.11.1. Company Overview
- 8.2.11.2. Financial Performance
- 8.2.11.3. Product/Service Benchmarking
- 8.2.11.4. Strategic Initiatives
- 8.2.12. Cook Medical
- 8.2.12.1. Company Overview
- 8.2.12.2. Financial Performance
- 8.2.12.3. Product/Service Benchmarking
- 8.2.12.4. Strategic Initiatives
- 8.2.13. W. L. Gore & Associates
- 8.2.13.1. Company Overview
- 8.2.13.2. Financial Performance
- 8.2.13.3. Product/Service Benchmarking
- 8.2.13.4. Strategic Initiatives
- 8.2.14. Integra LifeSciences
- 8.2.14.1. Company Overview
- 8.2.14.2. Financial Performance
- 8.2.14.3. Product/Service Benchmarking
- 8.2.14.4. Strategic Initiatives
- 8.2.15. Zimmer Biomet
- 8.2.15.1. Company Overview
- 8.2.15.2. Financial Performance
- 8.2.15.3. Product/Service Benchmarking
- 8.2.15.4. Strategic Initiatives